Korean ISBM Industry 4.0 framework<\/a> provides as an automated capability.<\/li>\n<\/ul>\n<\/section>\n<\/p>\n\n7. Cleanroom Production Standards for Korean ISBM Medical Device Packaging<\/h2>\nKorean ISBM medical device cleanroom production \u2014 ISO Class 8 (ISO 14644-1, \u2264 3,520,000 particles\/m\u00b3 \u2265 0.5\u03bcm) is the standard production environment for Korean Class II IVD reagent bottles and Class III medical device contact containers. The ISBM process itself \u2014 one-step injection and blowing in a closed machine \u2014 is inherently cleaner than two-stage SBM (which transfers preforms through open ambient air). Korean ISBM’s closed processing is a compliance advantage: the bottle interior is formed in the blow cavity without ambient exposure until ejection, meaning the controlled ejection environment determines the final interior contamination risk.<\/figcaption><\/figure>\nKorean KFDA GMP (\uc758\ub8cc\uae30\uae30\uc758 \uc81c\uc870 \ubc0f \ud488\uc9c8\uad00\ub9ac \uae30\uc900) requires medical device manufacturers to establish and maintain clean production environments appropriate to the risk level of the device being manufactured. For Korean primary container ISBM production, the relevant standard is ISO 14644-1 (Cleanrooms and associated controlled environments). Korean ISBM medical device packaging production environment requirements by device class:<\/p>\n
\nKorean Class I (\uc2e0\uace0):<\/strong> No formal cleanroom standard required \u2014 a general industrial production environment with documented HVAC filtration (MERV 8 or equivalent, replacing standard open factory air intake) and basic housekeeping procedures. Airborne particle monitoring quarterly recommended but not mandatory.<\/li>\nKorean Class II (\uc778\uc99d) \u2014 IVD reagent containers:<\/strong> ISO 14644-1 Class 8 production environment (\u2264 3,520,000 particles\/m\u00b3 at \u2265 0.5\u03bcm, equivalent to the old US Federal Standard 209E Class 100,000). Practical implementation: HEPA-filtered air supply to the production area, positive pressure differential (\u2265 +15 Pa) relative to adjacent non-production areas, gowning requirements (hair covers, dust coats, boot covers), and quarterly airborne particle count monitoring per ISO 14644-2.<\/li>\nKorean Class III (\ud5c8\uac00) \u2014 direct contact device containers:<\/strong> ISO 14644-1 Class 7 production environment (\u2264 352,000 particles\/m\u00b3 at \u2265 0.5\u03bcm, equivalent to Class 10,000) for the ISBM machine and bottle ejection zone. Full cleanroom garments (full overalls, gloves, face masks), pass-through material entry with UV decontamination, continuous particle monitoring (real-time alarm at Class 7 limit exceedance), and annual cleanroom performance certification. Korean ISBM operations achieving Class 7 at ISBM ejection zone typically use a local laminar flow hood directly above the bottle ejection conveyor \u2014 more economical than building a full Class 7 room around the entire ISBM machine.<\/li>\n<\/ul>\n<\/section>\n<\/p>\n\n8. GMP Validation: IQ, OQ, and PQ for Korean ISBM Medical Device Lines<\/h2>\n \nKorean ISBM GMP validation protocol \u2014 IQ (Installation Qualification) confirms the machine is installed to specification; OQ (Operational Qualification) determines the validated process parameter ranges; PQ (Performance Qualification) demonstrates consistent production at nominal conditions meeting all quality specifications. The Korean KFDA \ud5c8\uac00 submission requires all three validation phases to be completed and documented before commercial production begins \u2014 a timeline that Korean ISBM producers must plan for at contract negotiation stage, typically 4\u20136 months from mould manufacture to PQ completion.<\/figcaption><\/figure>\nGMP IQ\/OQ\/PQ validation is the core of Korean Class III medical device container ISBM qualification. Each phase serves a distinct purpose and generates specific documentation for the KFDA \ud5c8\uac00 dossier.<\/p>\n
IQ (Installation Qualification):<\/strong> Confirms that the Korean ISBM machine, mould, and ancillary equipment (dryer, chiller, compressed air system) are installed in accordance with manufacturer specifications. IQ documentation for Korean KFDA Class III includes: machine serial number and model confirmation, calibration certificates for all measuring instruments (thermocouples, pressure transducers, weight scales) with KRISS traceability, utility verification (cooling water temperature, flow rate, blow air pressure, dewpoint at machine inlet), and cleanroom environmental measurement at installation (particle count, temperature, humidity, differential pressure). Korean Ever-Power provides machine-specific IQ documentation templates covering all required data fields for Korean KFDA medical device IQ protocol completion.<\/p>\nOQ (Operational Qualification):<\/strong> Determines the validated operating ranges for each critical process parameter by challenging the process at parameter extremes and confirming acceptable product at each level. Typical Korean ISBM OQ study: 3 levels of each critical parameter (nominal \u2212 5%, nominal, nominal + 5%) for conditioning temperature, blow dwell time, and injection fill pressure; 30-bottle samples at each parameter level; dimensional and quality measurements (weight, neck OD, haze, wall thickness at 5 positions, visual inspection) at each level. OQ acceptance criteria: all quality attributes within specification at all parameter levels \u2014 establishing the validated parameter ranges within which production must operate. Parameters that produce failing product at nominal \u00b1 5% require the nominal setpoint to be re-optimised and the OQ repeated \u2014 a common OQ finding for Korean ISBM Class III producers who have not previously produced to Class III precision tolerances.<\/p>\nPQ (Performance Qualification):<\/strong> Demonstrates that the Korean ISBM process produces consistent specification-compliant product at nominal conditions over a minimum of 3 consecutive production runs at commercial scale. PQ sampling plan: minimum 125 bottles per cavity per run (total 375 per cavity for 3 runs), measured at 9 quality attributes including dimensional measurements, weight, haze, visual inspection per AQL Level II (ANSI\/ASQ Z1.4 \/ ISO 2859-1), and biocompatibility sample production confirmation. PQ statistical analysis: process capability (Cpk) \u2265 1.33 for each critical quality attribute \u2014 the Korean KFDA Class III standard for validated manufacturing capability. EV servo ISBM Korean platforms consistently achieve Cpk \u2265 1.50 for bottle weight and neck OD at nominal conditions; hydraulic Korean platforms typically achieve Cpk 1.00\u20131.20, which is below the Korean Class III standard and necessitates the hydraulic-to-EV-servo upgrade that Korean ISBM producers entering Class III supply consistently encounter as a prerequisite for successful PQ completion.<\/p>\n<\/section>\n<\/p>\n\n\u0427\u0435\u0441\u0442\u043e \u0437\u0430\u0434\u0430\u0432\u0430\u043d\u0438 \u0432\u044a\u043f\u0440\u043e\u0441\u0438<\/h2>\n\n
\n
\n
Q1 \u2014 What is the minimum Korean ISBM investment for entering Korean Class II IVD medical device packaging supply?<\/p>\n<\/div>\n
\n
The minimum investment for a Korean ISBM producer to qualify as a Korean Class II IVD reagent container supplier to a Korean notified body (\uc778\uc99d\uae30\uad00) certified medical device manufacturer comprises four components. (1) Quality system upgrade to ISO 13485:2016: Korean ISBM producers already operating under ISO 9001:2015 can achieve ISO 13485 upgrade in 6\u20139 months for KRW 8\u201315M (gap analysis, documentation revision, audit, certification) with a Korean accredited certification body. ISO 13485 is the Korean medical device quality management standard referenced in KFDA \uc778\uc99d process requirements. (2) ISO 10993-5 cytotoxicity test on production samples: KRW 1.5\u20133M at KTR or KCL; produces the biocompatibility certificate the Korean notified body requires. (3) Production environment upgrade to ISO 14644-1 Class 8: for a Korean ISBM production area of 80\u2013120 m\u00b2, HEPA filtration retrofit and positive pressure management: KRW 15\u201330M including validation. (4) GMP documentation system: batch records, equipment calibration programme, supplier qualification for resin and masterbatch, annual management review. If implemented from scratch: KRW 5\u201310M for documentation development and staff training. Total minimum investment: KRW 30\u201358M over 12\u201318 months. The corresponding commercial benefit: Korean Class II IVD medical device container pricing is typically KRW 45\u2013120\/bottle \u2014 2\u20134\u00d7 the margin per bottle of equivalent Korean commodity packaging \u2014 and Korean medical device manufacturer contracts are typically 3\u20135 year supply agreements, providing revenue stability unavailable in Korean commodity packaging markets.<\/p>\n<\/div>\n<\/div>\n
\n
\n
Q2 \u2014 How does Korean ISBM one-step processing differ from two-stage SBM for Korean medical device compliance purposes?<\/p>\n<\/div>\n
\n
Korean ISBM one-step processing has two compliance advantages over two-stage SBM (stretch blow moulding from pre-manufactured preforms) for Korean medical device applications. First, fewer process steps requiring individual validation: two-stage SBM requires separate GMP validation of preform injection moulding (IQ\/OQ\/PQ for the injection moulding machine) plus separate GMP validation of the reheat SBM process \u2014 two separate validation exercises, two sets of equipment calibration, two production environments to qualify under ISO 14644. Korean one-step ISBM combines both steps in a single validated process with one IQ\/OQ\/PQ protocol, approximately halving the validation effort. Second, no preform inventory and handling compliance requirement: two-stage SBM creates an intermediate preform inventory that must be stored in a qualified environment, tracked by lot number, and controlled for storage time limits (PET preforms degrade in crystallinity if stored too long before blowing). Korean one-step ISBM eliminates the preform storage compliance requirement entirely \u2014 the preform is made and immediately blown in the same cycle, with no intermediate product requiring environmental controls, lot traceability, or shelf-life management. For Korean pharmaceutical ISBM, this advantage is well-recognised. For Korean medical device ISBM, it is equally relevant \u2014 Korean Class III \ud5c8\uac00 submission documentation is simplified by one-step processing because the number of critical process steps requiring individual validation is reduced, shortening the IQ\/OQ\/PQ timeline by 2\u20134 months compared to a two-stage production process qualification.<\/p>\n<\/div>\n<\/div>\n
\n
\n
Q3 \u2014 Does gamma irradiation change the extractables profile of Korean ISBM PET medical device bottles?<\/p>\n<\/div>\n
\n
Yes \u2014 gamma irradiation generates free radicals in PET that produce a distinct set of radiation-induced degradation products in addition to the thermal degradation products present before irradiation. The primary radiation-induced extractables from Korean ISBM PET at 25 kGy are: (1) Increased acetaldehyde (gamma irradiation breaks additional ester bonds in the PET chain, releasing additional AA above the thermal AA from the ISBM process); (2) Vinyl alcohol oligomers (gamma scission of terminal vinyl groups); (3) Elevated PET cyclic oligomers (radiation promotes additional oligomer formation from chain scission). For Korean KFDA Class III medical device containers that are gamma-sterilised, the E&L study must be conducted on irradiated samples \u2014 not on unirradiated production samples \u2014 because the radiation-induced extractables are part of the container’s actual chemical profile that patients are exposed to. Korean ISBM producers who conduct their E&L study on unirradiated bottles and then sterilise by gamma have a deficiency in their Korean KFDA \ud5c8\uac00 dossier that becomes apparent only at KFDA review, requiring a repeat E&L study on irradiated samples and delaying the \ud5c8\uac00 approval by 3\u20136 months. Specify in the E&L test protocol from the outset that samples must be irradiated at the maximum intended dose before extraction \u2014 saving the repeat study cost and approval delay.<\/p>\n<\/div>\n<\/div>\n
\n
\n
Q4 \u2014 How does acetaldehyde in Korean ISBM PET affect medical device reagent quality?<\/p>\n<\/div>\n
\n
Acetaldehyde (AA) migration from Korean ISBM PET bottles into medical device reagents is a relevant quality concern for specific Korean IVD reagent categories \u2014 particularly enzyme-based diagnostic reagents where AA can react with enzyme active sites, and immunoassay reagents where AA can react with antibody proteins through Maillard reactions, reducing assay sensitivity. The AA migration threshold that causes measurable Korean IVD reagent performance degradation depends on the specific reagent matrix \u2014 enzyme-based IVD reagents show performance degradation at AA concentrations above 15 ppb in the stored reagent; immunoassay reagents are typically unaffected at Korean ISBM PET AA levels (1\u20138 ppb headspace AA in a 100ml PET bottle at ambient temperature, 3 months storage). Korean ISBM producers supplying Korean IVD diagnostic companies must disclose the measured headspace AA in bottles produced at commercial conditions (conditioning temperature, barrel temperature, cycle time) to the Korean medical device customer’s formulation team \u2014 and commit to maintaining AA below the agreed limit in all commercial production through process parameter controls and annual verification testing. The main ISBM parameter levers for reducing AA in Korean medical device PET bottles are: minimise barrel temperature (target 265\u00b0C zone 1, not 280\u00b0C+), minimise barrel residence time (do not leave PET in the barrel at temperature during stoppages above 10 minutes), and minimise conditioning dwell time (minimum adequate for quality, not maximum).<\/p>\n<\/div>\n<\/div>\n
\n
\n
Q5 \u2014 What Korean ISBM change control requirements apply after achieving Korean Class III KFDA \ud5c8\uac00?<\/p>\n<\/div>\n
\n
Korean KFDA \ud5c8\uac00-approved medical device packaging is subject to change control requirements that bind the Korean ISBM packaging manufacturer once the container specification is included in the Korean device manufacturer’s \ud5c8\uac00 dossier. Changes to the ISBM container that require Korean KFDA change notification (\ubcc0\uacbd\ud5c8\uac00 or \ubcc0\uacbd\uc2e0\uace0 depending on significance) and potentially a Korean KFDA review and re-approval include: changes to resin grade or manufacturer; changes to colorant or masterbatch specification; changes to the ISBM machine (model, serial number, location); significant process parameter changes outside the validated range established in OQ; and dimensional specification changes above the approved tolerance in the \ud5c8\uac00 dossier. Changes that typically do not require KFDA change notification (but do require internal change control documentation): within-range process parameter adjustments, ISBM operator certification changes, production environment improvements that maintain or exceed the validated cleanroom class. Korean ISBM packaging producers who treat their validated medical device container process as mutable \u2014 adjusting barrel temperatures without change control, substituting resin grades without supplier qualification, or moving ISBM machines between facilities without KFDA notification \u2014 create Korean KFDA compliance deficiencies that emerge at the device manufacturer’s next KFDA inspection, triggering corrective action requirements against the packaging supplier. The practical implication: ISBM producers entering Korean Class III medical device supply should dedicate a specific machine, mould, and resin supply chain to the medical device contract, with a change control system that prevents any change without formal review and, where required, Korean KFDA notification.<\/p>\n<\/div>\n<\/div>\n
\n
\n
Q6 \u2014 How does Korean ISBM dimensional precision compare to glass for Korean medical device container neck OD compliance?<\/p>\n<\/div>\n
\n
Korean ISBM PET and PETG bottles achieve neck OD dimensional precision of \u00b10.04mm (4-sigma, EV servo platform) at 4-cavity production \u2014 equivalent to or superior to pharmaceutical-grade glass bottle neck OD precision (typically \u00b10.05\u20130.10mm depending on glass moulding process and neck size). For Korean medical device applications where the closure (snap-cap, luer connector, septum) depends on neck OD tolerance for leak-free sealing, Korean ISBM’s \u00b10.04mm precision provides more consistent closure performance than glass’s \u00b10.05\u20130.10mm, with the additional advantage of being quantifiably verified per cavity in production (glass manufacturers provide dimensional certification at statistical sample level, not per-cavity). Two Korean medical device container requirements where glass retains an advantage over Korean ISBM PET\/PETG: (1) UV barrier for highly photosensitive reagents \u2014 amber glass blocks \u226599.9% of UV below 450nm; amber PET or amber PETG blocks 95\u201399% but requires validated masterbatch and migration testing; (2) Water vapour transmission rate (WVTR) \u2014 glass has zero WVTR; PET WVTR is approximately 1.5\u20133.0 g\u00b7mm\/m\u00b2\u00b7day at 38\u00b0C\/90% RH \u2014 acceptable for most aqueous IVD reagents at standard Korean laboratory storage (15\u201330\u00b0C) but requires humidity barrier closure for reagents sensitive to dilution from atmospheric moisture absorption over 18+ month shelf life.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n
<\/p>\n
\n
Medical Device Qualification Support<\/p>\n
Entering Korean KFDA Class II or Class III Medical Device Packaging? Need GMP Validation, ISO 10993, or IQ\/OQ\/PQ Support?<\/h2>\n Korean Ever-Power provides KFDA Class II\/III documentation templates, GMP IQ\/OQ\/PQ protocol development, biocompatibility sample production, EV servo process logging for KFDA Annex 11 compliance, and cleanroom ISBM commissioning for Korean medical device packaging qualification.<\/p>\n
Request Medical Device Qualification Support<\/a><\/p>\n<\/div>\n<\/p>\n\n\u0421\u0432\u044a\u0440\u0437\u0430\u043d\u0438 \u0440\u0435\u0441\u0443\u0440\u0441\u0438<\/p>\n
\n
Premium Medical Grade<\/span> \nInjection Stretch Blow Moulding Machine HGY150-V4-EV<\/span> \nAll-electric EV servo \u00b7 KFDA Annex 11 GMP data logging \u00b7 Cpk \u2265 1.50 for Class III PQ requirement \u00b7 Korean medical device IQ\/OQ\/PQ documentation package available.<\/span><\/div>\n <\/p>\n
Class II IVD Platform<\/span> \n\u041c\u0430\u0448\u0438\u043d\u0430 \u0437\u0430 \u0448\u043f\u0440\u0438\u0446\u0432\u0430\u043d\u0435 \u0438 \u0440\u0430\u0437\u0442\u044f\u0433\u0430\u043d\u0435 HGY200-V4<\/span> \nMulti-resin PET \/ PETG \/ PP \u00b7 \u00b10.04mm neck OD precision \u00b7 Korean Class II ISO 13485 compatible \u00b7 Radiation-stabilised PET grade validated \u00b7 IVD reagent bottle 15\u2013500ml.<\/span><\/div>\n <\/p>\n
High-Volume Medical<\/span> \n\u041c\u0430\u0448\u0438\u043d\u0430 \u0437\u0430 \u0448\u043f\u0440\u0438\u0446\u0432\u0430\u043d\u0435 \u0438 \u0440\u0430\u0437\u0442\u044f\u0433\u0430\u043d\u0435 HGY250-V4<\/span> \nLarge IVD reagent kit bottle production \u00b7 6-cavity Korean Class II output \u00b7 Cleanroom-compatible ejection system \u00b7 Wide-mouth 86mm neck for large diagnostic reagent containers.<\/span><\/div>\n <\/p>\n<\/div>\n<\/section>\n
<\/p>\n\n\u0420\u0435\u0434\u0430\u043a\u0442\u043e\u0440: Cxm<\/p>\n<\/footer>\n<\/div>\n
<\/p>","protected":false},"excerpt":{"rendered":"
Application of ISBM \u00b7 Medical Device Packaging \u00b7 Korean ISBM 2026 ISBM Medical Device Bottle Production: Korean Regulatory Guide Korean medical device packaging is the highest-compliance ISBM application \u2014 where every bottle must be biocompatibility-tested, sterilisation-validated, dimensionally qualified to GMP IQ\/OQ\/PQ standards, and manufactured in a documented clean environment. Korean ISBM producers who enter this […]<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[24],"tags":[],"class_list":["post-966","post","type-post","status-publish","format-standard","hentry","category-technical-deep-dive"],"_links":{"self":[{"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/posts\/966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/comments?post=966"}],"version-history":[{"count":1,"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/posts\/966\/revisions"}],"predecessor-version":[{"id":967,"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/posts\/966\/revisions\/967"}],"wp:attachment":[{"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/media?parent=966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/categories?post=966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/tags?post=966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}